IgE-mediated food allergy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, GOS, MOS and MPS could be applied to desensitize shrimp TM-induced food allergy through glycation, while FOS was not suitable to reduce TM allergenicity.
|
31442704 |
2020 |
Rheumatoid Arthritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of pain intensity in people with rheumatoid arthritis using the MOS intensity scale.
|
29807861 |
2019 |
Asthenia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
Back Pain
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
They used a self-administered the Roland Morris Disability Questionnaire (RDQ), the Japanese Orthopaedic Association Back Pain Questionnaire (JOABPEQ), MOS 36-Item Short-Form Health Survey (SF-36), and satisfaction for surgery (VAS) were completed.
|
31806423 |
2019 |
Diarrhea
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
Dysmenorrhea
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
Pelvic Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
The current study examines how stroke severity (NIH Stroke Scale), its impact on perceived mobility (Stroke Impact Scale mobility domain), and the environment (MOS Social Support-Positive Social Interactions scale and Measure of Stroke Environment receptivity and built environment domains) influence social participation (Activity Card Sort: ACS).
|
30800187 |
2019 |
Dyschezia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
Cancer Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Pain and Medical Outcomes Study Sleep questionnaire (MOS-Sleep) were assessed at baseline and 3 months after opioid titration in 231 opioid naïve CNCP patients.
|
30700073 |
2019 |
Pelvic pain female
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
Arthritis, Psoriatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition to clinical characteristics including presence of exposed lesions, data were collected using the Psoriatic Arthritis (PsA) Screening and Evaluation (PASE), Dermatology Life Quality Index (DLQI), MOS 36-Item Short-Form Health Survey (SF-36), Work Productivity and Activity Impairment Questionnaire Psoriasis (WPAI: PSO) and Medication Satisfaction Questionnaire (MSQ).
|
29430733 |
2018 |
Eating Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Participants completed a battery of established self-report measures assessing food addiction, binge-eating and eating-disorder psychopathology (Eating Disorder Examination-Questionnaire; EDE-Q), depressive symptoms (Patient Health Questionnaire-2; PHQ-2), and mental and physical functioning (MOS Short Form Health Survey; SF-12).
|
29870970 |
2018 |
Fibromyalgia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The scores in all sleep dimensions of the MOS-sleep were higher in CPP (more disturbances) compared to pain free patients, and differences were observed among the three groups of PCP, with FM most severely affected.
|
28945136 |
2018 |
Irritable Bowel Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The secondary outcome measures will include the MOS 36-item short-form health survey (SF-36), IBS Quality of Life Questionnaire (IBS-QOL), severity of IBS symptoms (IBS-SSS), and rectal perception.
|
30572430 |
2018 |
Neuralgia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Convergent validity was demonstrated with total score and MOS-36 Bodily Pain (Pearson correlation -0.79), Neuropathic Pain Symptom Inventory (0.73), Roland-Morris Disability Questionnaire (0.67), and MOS-36 Physical Functioning (-0.65).
|
29432327 |
2018 |
Degenerative polyarthritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, knee function will be measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, and the quality of life will be measured using the MOS Item Short-form Health Survey (SF-36).
|
29764409 |
2018 |
Depressive Symptoms
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Participants completed a battery of established self-report measures assessing food addiction, binge-eating and eating-disorder psychopathology (Eating Disorder Examination-Questionnaire; EDE-Q), depressive symptoms (Patient Health Questionnaire-2; PHQ-2), and mental and physical functioning (MOS Short Form Health Survey; SF-12).
|
29870970 |
2018 |
Ichthyosis Bullosa of Siemens
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The secondary outcome measures will include the MOS 36-item short-form health survey (SF-36), IBS Quality of Life Questionnaire (IBS-QOL), severity of IBS symptoms (IBS-SSS), and rectal perception.
|
30572430 |
2018 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
The K-MOS-HIV health survey appears to be a reliable and valid measure of HRQOL.
|
29764440 |
2018 |
Diffuse Intrinsic Pontine Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Classifying patients according to the recently developed DIPG survival prediction model, intermediate risk patients (n = 4), showed a PFS and MOS of 6.4 and 12.4 months, respectively, versus a PFS and MOS of 4.5 and 8.1 months, respectively, in high risk patient (n = 5).
|
28748343 |
2017 |
Stomach Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The methylation level of MOS was significantly elevated in patients with metachronous gastric neoplasms compared age- and sex-matched patients without metachronous gastric neoplasms (p=0.020).
|
26087797 |
2016 |
Intestinal metaplasia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In MOS, decrease of its methylation level following H. pylori eradication was significant among controls without intestinal metaplasia (IM) (p-value for slope < 0.05); however, it was not observed among patients with IM or those with dysplasia or gastric cancer.
|
23595635 |
2013 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Hypomethylation of MOS in GC tissues was associated with tumour invasion, nodal metastasis, and undifferentiated histology (p < 0.05).
|
22252584 |
2012 |
Liver diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
All patients and controls completed one generic HRQL questionnaire (MOS SF-36) and one liver-disease specific instrument (Chronic Liver Disease Questionnaire, CLDQ).
|
17406828 |
2007 |